New insights into disability accrual in patients with secondary-progressive MS

Continuing the use of disease-modifying therapies (DMTs) in patients with secondary-progressive MS (SPMS) who are actively relapsing is justified, new research findings suggest.

At ECTRIMS 2018, Dr Nathaniel Lizak from the Clinical Outcomes Research (CORe) Unit at the University of Melbourne, Australia, presented the details of a study set up to evaluate factors influencing the rate of disability accumulation and progression in patients with SPMS.

続きを読む

ログインまたは新規会員登録するとneurodiemのすべてのコンテンツにアクセスできます。

会員登録がお済みの方はこちら ログイン

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.